Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs ORKA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ORKA Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 2–3 Matrix Metrics)

ORKA Overall Winner 6-Pillar Tally: SYRE 0 – 3 ORKA (3 Tie) Matrix Metrics: SYRE 3 – 2 ORKA

As of Nov 16, 2026, Oruka Therapeutics, Inc. (ORKA) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas ORKA carries 38.8/100 (SELL) at $99.53 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although ORKA compares more favorably head-to-head, both SYRE (36.1/100 SELL) and ORKA (38.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs ORKA
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $98.90 · SMA50: $91.75
ORKA NASDAQ Head-to-Head Winner
Oruka Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.53
-5.52% 1D
Market Cap $7.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.34β · 66% Vol
Unified Composite Score
38.8 / 100 SELL
Tech 8.0 Fund 40.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 57.8 · SMA20: $96.21 · SMA50: $89.85

6-Pillar Scorecard Institutional Category Breakdown (SYRE 0 – 3 ORKA)

Columns: Metric · SYRE · ORKA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) -99.7% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $9.8B $7.1B
3. Profitability & Quality ORKA
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -35.0% -18.1%
4. Balance Sheet & Cash Flow ORKA
Cash Generation (TTM) N/A -$124M
Cash Flow Margin N/A N/A
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $189M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ORKA
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 87.9% (10th %ile) 78.7% (19th %ile)
Put/Call OI Skew N/A 0.26x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (3) vs ORKA (2)
Institutional Metric SYRE ORKA Criterion Row Edge
Market Capitalization
Scale
$9.8B $7.1B Larger Scale SYRE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-35.0% -18.1% Higher ROE ORKA
52-Week Range Position
Momentum
88% ($22–$111) 82% ($25–$116) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 1.34β · 66% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
36.1 / 100 (SELL) 38.8 / 100 (SELL) Higher Composite ORKA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) -$124M ($189M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ORKA +13.26 pp
SYRE: +25.11% · ORKA: +38.37%
3M Horizon SYRE +4.69 pp
SYRE: -7.29% · ORKA: -11.98%
6M Horizon ORKA +27.96 pp
SYRE: +42.64% · ORKA: +70.6%
1Y Horizon SYRE +64.45 pp
SYRE: +341.74% · ORKA: +277.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs ORKA. Trailing 12-month operating profitability (SYRE 0.0% vs ORKA 0.0%) and valuation multiples (SYRE N/M vs ORKA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
ORKA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-18.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ORKA BREAKOUT
141d in phase · OBV ACCUMULATION
Current IV 78.7%
IV Percentile 19th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ORKA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ORKA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs ORKA Key Questions & Quantitative Answers

As of Nov 16, 2026, Oruka Therapeutics, Inc. (ORKA) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas ORKA carries 38.8/100 (SELL) at $99.53 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although ORKA compares more favorably head-to-head, both SYRE (36.1/100 SELL) and ORKA (38.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SYRE and ORKA split Growth & Scale metrics: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ORKA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus N/A for ORKA. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ORKA.

SYRE and ORKA trade at balanced relative valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ORKA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus ORKA (-18.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, ORKA carries 78.7% implied volatility (19th %ile, Compressed (<25th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.34β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.